{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:09:21Z","timestamp":1788696561937,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.104113","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:13Z","timestamp":1785283213000},"page":"104113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease Kinetics and Practice Patterns in More Than or Equal to 4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced NSCLC"],"prefix":"10.1016","author":[{"given":"Masahiro","family":"Torasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiki","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Naoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104113_bib1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jtho.2025.06.028","article-title":"50 years of progress in NSCLC: a new fellow\u2019s guide in the clinic","volume":"20","author":"Naidoo","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jtho.2025.05.019","article-title":"Treatment-free survival over 6 years of follow-up in patients with metastatic NSCLC treated with first-line nivolumab plus ipilimumab versus chemotherapy in CheckMate 227 Part 1","volume":"20","author":"Peters","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105123","article-title":"Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA","volume":"10","author":"Carbone","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.104113_bib11","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study","volume":"43","author":"Rousseau","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtho.2026.104113_bib12","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/1078-0432.CCR-23-1207","article-title":"Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"29","author":"Thummalapalli","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.104113_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2026.104113_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.resinv.2023.10.004","article-title":"Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors","volume":"62","author":"Tamiya","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.jtho.2026.104113_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cllc.2022.03.008","article-title":"Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings","volume":"23","author":"Yoneda","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.104113_bib16","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-24-2990","article-title":"Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer","volume":"31","author":"Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.104113_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/OP.23.00716","article-title":"Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations","volume":"20","author":"Hart","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtho.2026.104113_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib19","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jtho.2024.04.011","article-title":"Pembrolizumab plus chemotherapy for metastatic NSCLC with programmed cell death ligand 1 tumor proportion score less than 1%: pooled analysis of outcomes after five years of follow-up","volume":"19","author":"Gadgeel","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.annonc.2025.12.011","article-title":"PET\/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)","volume":"37","author":"Frost","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib25","article-title":"Late immune-related adverse events after at least two years of immune checkpoint inhibitor therapy: incidence and association with survival in patients with advanced NSCLC","volume":"6","author":"Elghawy","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.104113_bib26","doi-asserted-by":"crossref","first-page":"S2084","DOI":"10.1016\/j.annonc.2025.10.758","article-title":"1047P Pembrolizumab (Pembro) monotherapy for locally advanced or metastatic non\u2013small-cell lung cancer (NSCLC): 10-year outcomes from clinical trials","volume":"36","author":"Garon","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820954461","article-title":"The change trend of cause of death in patients with stage I non-small cell lung cancer after surgery in US: a long-term follow-up study based on SEER database","volume":"27","author":"Peng","year":"2020","journal-title":"Cancer Control"},{"key":"10.1016\/j.jtho.2026.104113_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.athoracsur.2010.04.100","article-title":"Conditional cancer-specific versus cardiovascular-specific survival after lobectomy for stage I non-small cell lung cancer","volume":"90","author":"Groth","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2026.104113_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/annonc\/mdv061","article-title":"Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis","volume":"26","author":"Janssen-Heijnen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jtcvs.2018.09.119","article-title":"Imaging surveillance for surgically resected stage I non-small cell lung cancer: is more always better?","volume":"157","author":"Subramanian","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2026.104113_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djac208","article-title":"Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer","volume":"115","author":"Heiden","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2026.104113_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jss.2015.06.048","article-title":"Imaging surveillance and survival for surgically resected non-small-cell lung cancer","volume":"200","author":"Backhus","year":"2016","journal-title":"J Surg Res"},{"key":"10.1016\/j.jtho.2026.104113_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5761\/atcs.oa.24-00093","article-title":"The interval of computed tomography follow-ups after advanced non-small-cell lung cancer surgery did not show any relationship with survival","volume":"30","author":"Maru","year":"2024","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2026.104113_bib34","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.23.02475","article-title":"Surveillance imaging after curative-intent treatment for cancer: benefits, harms, and evidence","volume":"42","author":"Wilson","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104113_bib35","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.19.02748","article-title":"Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline","volume":"38","author":"Schneider","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T11:11:52Z","timestamp":1788693112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426005666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S1556086426005666"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104113","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease Kinetics and Practice Patterns in More Than or Equal to 4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"104113"}}